Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS-1 olverembatinib plus chemotherapy versus investigator's choice TKI plus chemotherapy in newly diagnosed Ph+ ALL
2024-511496-14-00Phase 3Authorised
- Sponsor
- Ascentage Pharma
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of olverembatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Ascentage Pharma. Primary endpoint: MRD-negative complete remission rate at end of induction. Planned start May 2026; status: authorised.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-511496-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511496-14-00.